<div>Quadria Capital, a healthcare-focussed private equity (PE) fund, is set to investRs.500 crore for a 20% stake in drug maker Concord Biotech Ltd, after valuing the company at nearlyRs.2,500 crore, said three people familiar with the development. “The deal closure is expected before the end of this month; (the) final contours are being worked out right now,” said the first person mentioned above requesting anonymity as the discussions are confidential.</div>